In a recent video interview with Applied Clinical Trials, Jonathan Andrus, Co-CEO of CRIO, outlines the operational shifts that will most impact clinical trial execution in 2026. He highlights the accelerating move toward site-based technologies and protocol-driven eSource to ensure data quality, compliance, and patient data reliability at the point of patient encounter. Andrus explains why traditional paper processes and fragmented systems no longer meet the needs of modern trials, and why sponsors are increasingly prioritizing trusted electronic source solutions that seamlessly feed downstream systems like EDC and clinical data warehouses. The discussion also explores the broader transition from traditional clinical data management to clinical data science, where analytics and real-time oversight play a central role in driving study efficiency and performance. Read the full interview to learn how these trends are reshaping the future of clinical trial technology.